Susquehanna International Group’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $132K | Sell |
84,400
-51,700
| -38% | -$75.2K | ﹤0.01% | 12138 |
|
|
2025
Q4 | $157K | Buy |
136,100
+4,700
| +4% | +$6.46K | ﹤0.01% | 11130 |
|
|
2025
Q3 | $177K | Buy |
131,400
+43,900
| +50% | +$49.8K | ﹤0.01% | 11111 |
|
|
2025
Q2 | $83.1K | Buy |
87,500
+73,200
| +512% | +$47.4K | ﹤0.01% | 11890 |
|
|
2025
Q1 | $6.58K | Buy |
14,300
+3,500
| +32% | +$2.21K | ﹤0.01% | 12243 |
|
|
2024
Q4 | $7.99K | Buy |
+10,800
| New | +$13K | ﹤0.01% | 11993 |
|
|
2024
Q3 | – | Sell |
-171,800
| Closed | -$289K | – | 12582 |
|
|
2024
Q2 | $289K | Sell |
171,800
-119,100
| -41% | -$214K | ﹤0.01% | 9534 |
|
|
2024
Q1 | $698K | Buy |
290,900
+132,100
| +83% | +$284K | ﹤0.01% | 7704 |
|
|
2023
Q4 | $243K | Buy |
158,800
+31,000
| +24% | +$36.9K | ﹤0.01% | 10280 |
|
|
2023
Q3 | $139K | Sell |
127,800
-56,000
| -30% | -$98.3K | ﹤0.01% | 10623 |
|
|
2023
Q2 | $421K | Buy |
183,800
+127,100
| +224% | +$337K | ﹤0.01% | 8716 |
|
|
2023
Q1 | $138K | Buy |
56,700
+29,900
| +112% | +$68.5K | ﹤0.01% | 10996 |
|
|
2022
Q4 | $51.2K | Buy |
26,800
+4,500
| +20% | +$9.58K | ﹤0.01% | 11389 |
|
|
2022
Q3 | $54K | Buy |
+22,300
| New | +$61.7K | ﹤0.01% | 12148 |
|
|
2022
Q2 | – | Sell |
-18,400
| Closed | -$38K | – | 13517 |
|
|
2022
Q1 | $38K | Sell |
18,400
-44,100
| -71% | -$122K | ﹤0.01% | 12425 |
|
|
2021
Q4 | $246K | Buy |
62,500
+38,800
| +164% | +$188K | ﹤0.01% | 10980 |
|
|
2021
Q3 | $114K | Sell |
23,700
-73,900
| -76% | -$303K | ﹤0.01% | 11978 |
|
|
2021
Q2 | $448K | Sell |
97,600
-15,800
| -14% | -$76.1K | ﹤0.01% | 9847 |
|
|
2021
Q1 | $666K | Sell |
113,400
-144,100
| -56% | -$998K | ﹤0.01% | 8787 |
|
|
2020
Q4 | $881K | Buy |
257,500
+195,100
| +313% | +$372K | ﹤0.01% | 7015 |
|
|
2020
Q3 | $90K | Buy |
62,400
+22,100
| +55% | +$39.3K | ﹤0.01% | 9968 |
|
|
2020
Q2 | $80K | Buy |
40,300
+15,300
| +61% | +$30K | ﹤0.01% | 9595 |
|
|
2020
Q1 | $49K | Sell |
25,000
-94,900
| -79% | -$282K | ﹤0.01% | 9694 |
|
|
2019
Q4 | $498K | Buy |
119,900
+31,900
| +36% | +$123K | ﹤0.01% | 6988 |
|
|
2019
Q3 | $265K | Sell |
88,000
-19,700
| -18% | -$61K | ﹤0.01% | 8568 |
|
|
2019
Q2 | $677K | Sell |
107,700
-109,400
| -50% | -$655K | ﹤0.01% | 6587 |
|
|
2019
Q1 | $1.21M | Buy |
217,100
+117,800
| +119% | +$716K | ﹤0.01% | 4652 |
|
|
2018
Q4 | $659K | Sell |
99,300
-83,500
| -46% | -$676K | ﹤0.01% | 5485 |
|
|
2018
Q3 | $1.95M | Buy |
182,800
+70,000
| +62% | +$802K | ﹤0.01% | 4039 |
|
|
2018
Q2 | $1.35M | Sell |
112,800
-19,600
| -15% | -$200K | ﹤0.01% | 4748 |
|
|
2018
Q1 | $1.14M | Buy |
132,400
+53,400
| +68% | +$494K | ﹤0.01% | 4983 |
|
|
2017
Q4 | $781K | Sell |
79,000
-204,000
| -72% | -$2.12M | ﹤0.01% | 5731 |
|
|
2017
Q3 | $3.48M | Buy |
283,000
+210,200
| +289% | +$3.1M | ﹤0.01% | 3007 |
|
|
2017
Q2 | $1.2M | Sell |
72,800
-155,900
| -68% | -$2.41M | ﹤0.01% | 4891 |
|
|
2017
Q1 | $3.28M | Buy |
228,700
+129,600
| +131% | +$1.92M | ﹤0.01% | 2903 |
|
|
2016
Q4 | $1.37M | Sell |
99,100
-94,200
| -49% | -$1.51M | ﹤0.01% | 4859 |
|
|
2016
Q3 | $3.49M | Buy |
193,300
+39,000
| +25% | +$628K | ﹤0.01% | 2689 |
|
|
2016
Q2 | $2.21M | Buy |
154,300
+131,600
| +580% | +$1.78M | ﹤0.01% | 3399 |
|
|
2016
Q1 | $271K | Sell |
22,700
-67,000
| -75% | -$702K | ﹤0.01% | 7429 |
|
|
2015
Q4 | $1.19M | Buy |
89,700
+13,400
| +18% | +$165K | ﹤0.01% | 5071 |
|
|
2015
Q3 | $819K | Buy |
+76,300
| New | +$833K | ﹤0.01% | 6155 |
|
Other funds holding LXRX
AG
SL
SC
VCM
Susquehanna International Group's LXRX Position: Q1 2026 in Review
Susquehanna International Group increased its Lexicon Pharmaceuticals (LXRX) stake by 76% in Q1 2026, buying an estimated $1.33M and bringing the position to 2,121,164 shares worth $3.31M. The position accounts for ﹤0.01% of the portfolio, ranked #5065.
Susquehanna International Group first reported a position in LXRX in Q2 2013 and has held it in 45 quarters since. The position peaked at $6.99M in Q2 2017. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.
- Susquehanna International Group held 2,121,164 shares of Lexicon Pharmaceuticals worth $3.31M as of Q1 2026.
- Susquehanna International Group bought 913,922 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $1.33M.
- Lexicon Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5065 holding.
- Susquehanna International Group first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- Susquehanna International Group's Lexicon Pharmaceuticals position peaked at $6.99M in Q2 2017.
- 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.